{"id":3303,"date":"2025-03-19T18:58:03","date_gmt":"2025-03-19T15:58:03","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3303"},"modified":"2025-03-19T18:58:05","modified_gmt":"2025-03-19T15:58:05","slug":"satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/satellos-presents-initial-data-from-the-phase-1-trial-of-sat-3247-at-the-2025-muscular-dystrophy-association-clinical-scientific-conference\/","title":{"rendered":"Satellos pr\u00e9sente les donn\u00e9es initiales de l&#039;essai de phase 1 de SAT-3247 lors de la conf\u00e9rence clinique et scientifique 2025 de la Muscular Dystrophy Association"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos Bioscience, une soci\u00e9t\u00e9 de biotechnologie d\u00e9veloppant de nouvelles approches th\u00e9rapeutiques \u00e0 petites mol\u00e9cules pour am\u00e9liorer le traitement des maladies et troubles musculaires, a annonc\u00e9 aujourd&#039;hui les donn\u00e9es initiales de la phase 1 lors d&#039;une pr\u00e9sentation orale lors de la conf\u00e9rence clinique et scientifique 2025 de la Muscular Dystrophy Association (MDA) \u00e0 Dallas, au Texas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le SAT-3247 est con\u00e7u pour traiter la perte musculaire progressive chez les patients atteints de DMD en cherchant \u00e0 restaurer la r\u00e9g\u00e9n\u00e9ration musculaire en r\u00e9ponse aux l\u00e9sions. Un essai de phase 1 avec le SAT-3247 est actuellement men\u00e9 chez des volontaires sains et des adultes atteints de DMD (phases 1a et 1b, respectivement).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En savoir plus: <a href=\"https:\/\/dmdwarrior.com\/fr\/satellos-announces-completed-enrollment-of-phase-1-clinical-trial-of-sat-3247-in-healthy-volunteers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos annonce la fin du recrutement de l&#039;essai clinique de phase 1 de SAT-3247 chez des volontaires sains<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lors de la phase 1a, visant \u00e0 \u00e9valuer l&#039;innocuit\u00e9 et la tol\u00e9rance du SAT-3247, 72 volontaires sains ont \u00e9t\u00e9 randomis\u00e9s en cinq cohortes \u00e0 dose unique croissante (SAD) (dont une cohorte \u00e0 effet alimentaire) recevant des doses orales uniques allant jusqu&#039;\u00e0 400 mg, et quatre cohortes \u00e0 dose maximale croissante (MAD) recevant des doses orales quotidiennes allant jusqu&#039;\u00e0 240 mg\/jour pendant 7 jours. Au 20 f\u00e9vrier 2025, date limite de collecte des donn\u00e9es\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Les donn\u00e9es de phase 1a ont montr\u00e9 que le SAT-3247 \u00e9tait s\u00fbr et bien tol\u00e9r\u00e9 dans toutes les cohortes de volontaires sains. Aux doses efficaces pr\u00e9vues chez l&#039;homme, le SAT-3247 n&#039;a entra\u00een\u00e9 aucun effet ind\u00e9sirable clinique sur aucun param\u00e8tre mesur\u00e9, notamment les analyses de laboratoire, les signes vitaux, l&#039;ECG et l&#039;examen physique. Aucun effet ind\u00e9sirable mod\u00e9r\u00e9 ou grave li\u00e9 au m\u00e9dicament n&#039;a \u00e9t\u00e9 signal\u00e9, quelle que soit la dose \u00e9tudi\u00e9e.<\/li>\n\n\n\n<li>Les donn\u00e9es pharmacocin\u00e9tiques de phase 1a ont d\u00e9montr\u00e9 une coh\u00e9rence avec les r\u00e9sultats des \u00e9tudes pr\u00e9cliniques de la Soci\u00e9t\u00e9. Ces r\u00e9sultats pharmacocin\u00e9tiques confirment que les concentrations plasmatiques post-dose de SAT-3247 se maintiennent \u00e0 des niveaux et \u00e0 des dur\u00e9es qui, selon les r\u00e9sultats, sont les plus susceptibles d&#039;avoir un effet th\u00e9rapeutique sur la r\u00e9g\u00e9n\u00e9ration et la force musculaires.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos pr\u00e9voit de communiquer les donn\u00e9es compl\u00e8tes des phases 1a et 1b au deuxi\u00e8me trimestre 2025.<\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos Bioscience, a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference in Dallas, Texas. SAT-3247 is designed to address progressive muscle loss in DMD patients [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3304,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[297,251,252,253],"class_list":["post-3303","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-muscular-dystrophy-association","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"subtitle":"Satellos Bioscience a pr\u00e9sent\u00e9 des donn\u00e9es initiales prometteuses issues de son essai de phase 1 sur SAT-3247 lors de la conf\u00e9rence clinique et scientifique 2025 de la Muscular Dystrophy Association. L'essai de phase 1b en cours recrute des adultes atteints de DMD afin d'\u00e9valuer plus en d\u00e9tail la s\u00e9curit\u00e9 et la pharmacocin\u00e9tique du m\u00e9dicament. Les donn\u00e9es compl\u00e8tes sont attendues au deuxi\u00e8me trimestre 2025.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3303"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3304"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}